NCT02409004View on ClinicalTrials.gov

Effects of Rifampin on the Pharmacokinetics of Ataluren

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Healthy

Interventions

DRUG

Ataluren

Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)

DRUG

Rifampin

Capsule 2x3oo mg Oral

Trial Locations (1)

G1P 0A2

Inventiv, Québec

Sponsors

Lead Sponsor

PTC Therapeutics

All Listed Sponsors

lead

PTC Therapeutics

INDUSTRY